Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Volpara Health Technologies.
RELATED STOCKHEAD STORIES
Health & Biotech
Volpara cracks its biggest deal yet with US$2.15m partnership
Health & Biotech
ASX Health Stocks: Pharmaxis progresses to Phase 2 study on bone marrow cancer
Health & Biotech
ScoPo’s Powerplays: Market volatility creates both buying and selling opportunities in the Health sector
Health & Biotech
ASX Health Stocks: M&A winds blow as API gets an upgraded offer from Wesfarmers, jumps 15pc
Health & Biotech
Volpara gets on the fast track as a leading player in lung care with two strategic US partnerships
Health & Biotech
ScoPo’s Powerplays: Profit-taking on the cards for health stocks that have had good runs
Stockhead TV
90 Seconds With… Ralph Highnam, CEO, Volpara Health Technologies Limited
Health & Biotech
ScoPo’s Powerplays: Solid earnings for health stocks all round, but price action stays with larger caps
News
Closing Bell: ASX rebounds from yesterday’s fall, led by 2.6pc gain in tech
Health & Biotech
ScoPo’s Powerplays: Healthcare sector has bounced back as earnings season kicks off, expect to buy on the dips
Health & Biotech
ASX health stocks today: AdAlta (ASX:1AD) leads after successful Phase I study
News
Closing Bell: Market slips, but Materials up 1.23%
Health & Biotech
ScoPo’s Powerplays: ‘Go long equities’ as Nanosonics, Antisense, Volpara to benefit from V-shaped recovery
Health & Biotech
ScoPo’s Powerplays: ‘Prepare for a big jump in July’ as tax-loss selling in healthcare continues
Health & Biotech
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention
Health & Biotech
Breast cancer play Volpara delivers full-year bumper revenue, share price up 5pc
News